These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3917812)

  • 1. Circadian changes in anticoagulant effect of heparin infused at a constant rate.
    Decousus HA; Croze M; Levi FA; Jaubert JG; Perpoint BM; De Bonadona JF; Reinberg A; Queneau PM
    Br Med J (Clin Res Ed); 1985 Feb; 290(6465):341-4. PubMed ID: 3917812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nycthemeral change in the anticoagulant effect of heparin given at a constant rate by the intravenous route].
    Decousus H; Croze M; Levi F; Jaubert J; Perpoint B; Reinberg A; Queneau P
    C R Acad Sci III; 1985; 300(9):385-8. PubMed ID: 3922584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of activated partial thromboplastin time during constant intravenous and fixed intermittent subcutaneous administration of heparin.
    Fagrell B; Arver S; Intaglietta M; Tsai AG
    J Intern Med; 1989 Apr; 225(4):257-60. PubMed ID: 2723583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin kinetics in venous thrombosis and pulmonary embolism.
    Hirsh J; van Aken WG; Gallus AS; Dollery CT; Cade JF; Yung WL
    Circulation; 1976 Apr; 53(4):691-5. PubMed ID: 1253392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion. A study in healthy volunteers.
    Krulder JW; de Boer A; van den Besselaar AM; Cohen AF; Schoemaker HC; Briët E; Meinders AE
    Thromb Haemost; 1992 Jul; 68(1):30-2. PubMed ID: 1514169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of anticoagulant treatment measured by fibrinopeptide A (fpA) in patients with venous thrombo-embolism.
    Peuscher FW; van Aken WG; Flier OT; Stoepman-van Dalen EA; Cremer-Goote TM; van Mourik JA
    Thromb Res; 1980 Apr 1-15; 18(1-2):33-43. PubMed ID: 7404504
    [No Abstract]   [Full Text] [Related]  

  • 9. Antithrombotic therapy in deep vein thrombosis and pulmonary embolism.
    Hirsh J
    Am Heart J; 1992 Apr; 123(4 Pt 2):1115-22. PubMed ID: 1553881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.
    Basu D; Gallus A; Hirsh J; Cade J
    N Engl J Med; 1972 Aug; 287(7):324-7. PubMed ID: 5041701
    [No Abstract]   [Full Text] [Related]  

  • 11. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The successful application of a heparin nomogram in a community hospital.
    Hollingsworth JA; Rowe BH; Brisebois FJ; Thompson PR; Fabris LM
    Arch Intern Med; 1995 Oct; 155(19):2095-100. PubMed ID: 7575069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory control of continuous intravenous heparin therapy with Howel time and activated partial thromboplastin time. A prospective, randomized and blind study.
    Almazan A; Lozano F; Ramos M; Rodriguez-Moran M; Gomez-Alonso A
    Angiology; 1985 Jun; 36(6):363-9. PubMed ID: 4025944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol.
    Williams-Norwood T; Caswell M; Milner B; Vescera JC; Prymicz K; Ciszak AG; Ingle C; Lacey C; Stavrou EX
    AACN Adv Crit Care; 2020 Jun; 31(2):129-137. PubMed ID: 32526007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin therapy.
    Raich PC; Hahn MF; Korst DR
    Am Fam Physician; 1974 Sep; 10(3):163-8. PubMed ID: 4413661
    [No Abstract]   [Full Text] [Related]  

  • 16. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control and complications of intermittent heparin therapy.
    Norman CS; Provan JL
    Surg Gynecol Obstet; 1977 Sep; 145(3):338-42. PubMed ID: 888052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring heparin treatment with the APTT: the effect of methodological changes on the APTT.
    Krulder JW; van der Meer FJ; Briët E; Meinders AE
    Neth J Med; 1996 Jul; 49(1):13-8. PubMed ID: 8772354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the subcutaneous heparin pump during pregnancy.
    Barss VA; Schwartz PA; Greene MF; Phillippe M; Saltzman D; Frigoletto FD
    J Reprod Med; 1985 Dec; 30(12):899-901. PubMed ID: 4078826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin 1986. Indications and effective use.
    Ockelford P
    Drugs; 1986 Jan; 31(1):81-92. PubMed ID: 3510115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.